sub-component Search Results


q subcomponent binding protein habp1 c1qbp  (MedChemExpress)
94
MedChemExpress q subcomponent binding protein habp1 c1qbp
Q Subcomponent Binding Protein Habp1 C1qbp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/q subcomponent binding protein habp1 c1qbp/product/MedChemExpress
Average 94 stars, based on 1 article reviews
q subcomponent binding protein habp1 c1qbp - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
antigen retrieval  (Proteintech)
93
Proteintech antigen retrieval
Antigen Retrieval, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antigen retrieval/product/Proteintech
Average 93 stars, based on 1 article reviews
antigen retrieval - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
antibodies against c1qc  (Boster Bio)
93
Boster Bio antibodies against c1qc
Immunofluorescence results for <t>C1qc,</t> C9 and Clu (×400). (A) Immunofluorescence expression of <t>C1qc.</t> (B) Immunofluorescence expression of C9. (C) Immunofluorescence expression of Clu. Quantitative analysis of immunofluorescence results of (D) C1qc, (E) C9 and (F) Clu proteins. Relative expression of (G) C1qc, (H) C9 and (I) Clu proteins were analyzed by proteomic analysis. *P<0.05 or **P<0.01 vs. CN group in rats. C, complement; CN, control; Clu, clusterin.
Antibodies Against C1qc, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against c1qc/product/Boster Bio
Average 93 stars, based on 1 article reviews
antibodies against c1qc - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
human complement c1q  (Cusabio)
91
Cusabio human complement c1q
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
Human Complement C1q, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human complement c1q/product/Cusabio
Average 91 stars, based on 1 article reviews
human complement c1q - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
c1s  (Proteintech)
93
Proteintech c1s
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
C1s, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c1s/product/Proteintech
Average 93 stars, based on 1 article reviews
c1s - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
csb el003637mo  (Cusabio)
93
Cusabio csb el003637mo
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
Csb El003637mo, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/csb el003637mo/product/Cusabio
Average 93 stars, based on 1 article reviews
csb el003637mo - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
c1qb  (MedChemExpress)
93
MedChemExpress c1qb
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
C1qb, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c1qb/product/MedChemExpress
Average 93 stars, based on 1 article reviews
c1qb - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
mouse complement c1qa  (MedChemExpress)
93
MedChemExpress mouse complement c1qa
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
Mouse Complement C1qa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse complement c1qa/product/MedChemExpress
Average 93 stars, based on 1 article reviews
mouse complement c1qa - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
c1qa  (Cusabio)
90
Cusabio c1qa
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
C1qa, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c1qa/product/Cusabio
Average 90 stars, based on 1 article reviews
c1qa - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
catalog number hy p76929  (MedChemExpress)
93
MedChemExpress catalog number hy p76929
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
Catalog Number Hy P76929, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/catalog number hy p76929/product/MedChemExpress
Average 93 stars, based on 1 article reviews
catalog number hy p76929 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
c1qa  (Boster Bio)
92
Boster Bio c1qa
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
C1qa, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c1qa/product/Boster Bio
Average 92 stars, based on 1 article reviews
c1qa - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
space components and sub-systems  (Thales Alenia Space)
90
Thales Alenia Space space components and sub-systems
<t>Complement</t> in HBV-ACLF group, CHB group and control group. a The concentrations of <t>C1q</t> were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)
Space Components And Sub Systems, supplied by Thales Alenia Space, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/space components and sub-systems/product/Thales Alenia Space
Average 90 stars, based on 1 article reviews
space components and sub-systems - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Immunofluorescence results for C1qc, C9 and Clu (×400). (A) Immunofluorescence expression of C1qc. (B) Immunofluorescence expression of C9. (C) Immunofluorescence expression of Clu. Quantitative analysis of immunofluorescence results of (D) C1qc, (E) C9 and (F) Clu proteins. Relative expression of (G) C1qc, (H) C9 and (I) Clu proteins were analyzed by proteomic analysis. *P<0.05 or **P<0.01 vs. CN group in rats. C, complement; CN, control; Clu, clusterin.

Journal: Molecular Medicine Reports

Article Title: Proteomics analysis of lung tissue reveals protein makers for the lung injury of adjuvant arthritis rats

doi: 10.3892/mmr.2023.13051

Figure Lengend Snippet: Immunofluorescence results for C1qc, C9 and Clu (×400). (A) Immunofluorescence expression of C1qc. (B) Immunofluorescence expression of C9. (C) Immunofluorescence expression of Clu. Quantitative analysis of immunofluorescence results of (D) C1qc, (E) C9 and (F) Clu proteins. Relative expression of (G) C1qc, (H) C9 and (I) Clu proteins were analyzed by proteomic analysis. *P<0.05 or **P<0.01 vs. CN group in rats. C, complement; CN, control; Clu, clusterin.

Article Snippet: The sections were incubated with primary antibodies against C1qc (1:100; cat. no. A05666; Boster Biological Technology), C9 (1:100; cat. no. K107807P; Beijing Solarbio Science and Technology Co., Ltd.), Clu (1:100; cat. no. 12289-1-AP; Proteintech Group, Inc.) at 4°C overnight and washed with PBS 3 times (5 min each).

Techniques: Immunofluorescence, Expressing, Control

Complement in HBV-ACLF group, CHB group and control group. a The concentrations of C1q were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)

Journal: BMC Gastroenterology

Article Title: Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure

doi: 10.1186/s12876-020-01258-3

Figure Lengend Snippet: Complement in HBV-ACLF group, CHB group and control group. a The concentrations of C1q were significantly lower in HBV-ACLF group than that in CHB group or in control group ( P < 0.05). b There was no statistical significance of the plasma concentrations of MBL in all groups. c There was no statistical significance of the plasma concentrations of FB in all groups. d Complement C3 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). e Complement C3a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). f Complement C4 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). g Complement C4a was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). h Complement C5b-9 was significantly higher in the control group than that in the HBV-ACLF group ( P < 0.05). i The concentrations of C3 were significantly lower in the HBV-ACLF patients with pulmonary infection than that in the HBV-ACLF patients without pulmonary infection ( P < 0.05)

Article Snippet: Human Complement C1q, FB, MBL, C3, C3a, C4, C4a and sC5b-9 were measured with commercial ELISA kits (Cusabio Biotech, Wuhan, P.R.

Techniques: Control, Clinical Proteomics, Infection

Plasma levels of complement components in the HBV-ACLF, CHB group and health control groups

Journal: BMC Gastroenterology

Article Title: Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure

doi: 10.1186/s12876-020-01258-3

Figure Lengend Snippet: Plasma levels of complement components in the HBV-ACLF, CHB group and health control groups

Article Snippet: Human Complement C1q, FB, MBL, C3, C3a, C4, C4a and sC5b-9 were measured with commercial ELISA kits (Cusabio Biotech, Wuhan, P.R.

Techniques: Clinical Proteomics, Control

Relationship between complement components and clinical parameter. a C1q was observed to be positively correlated with AFP ( P < 0.05). b C3 was observed to be positively correlated with AFP ( P < 0.05). c C3a was observed to be negatively correlated with creatinine ( P < 0.05). d C4a was observed to be negatively correlated with creatinine ( P < 0.05). e C4 was observed to be negatively correlated with INR ( P < 0.05)

Journal: BMC Gastroenterology

Article Title: Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure

doi: 10.1186/s12876-020-01258-3

Figure Lengend Snippet: Relationship between complement components and clinical parameter. a C1q was observed to be positively correlated with AFP ( P < 0.05). b C3 was observed to be positively correlated with AFP ( P < 0.05). c C3a was observed to be negatively correlated with creatinine ( P < 0.05). d C4a was observed to be negatively correlated with creatinine ( P < 0.05). e C4 was observed to be negatively correlated with INR ( P < 0.05)

Article Snippet: Human Complement C1q, FB, MBL, C3, C3a, C4, C4a and sC5b-9 were measured with commercial ELISA kits (Cusabio Biotech, Wuhan, P.R.

Techniques: